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Analysis of 501 melanoma exomes revealed RASA2, encoding a RasGAP, as a tumor-suppressor 
gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to 
increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in 
≥30% of human melanomas and was associated with reduced patient survival. These findings 
reveal RASA2 inactivation as a melanoma driver and highlight the importance of Ras GAPs in 
cancer.
Cutaneous melanoma, for which incidence rates continue to increase 1, represents a 
significant health problem worldwide. Recent genomic studies of melanoma 2,3,4 have 
discovered several driver genes and enabled development of targeted drugs, which show 
promise in treating melanoma patients 5,6. However, responses are rarely durable; therefore 
there is an urgent need to identify additional targetable alterations in melanoma.
Most approved drugs that target genetically altered proteins in cancer are towards kinases 7. 
However, a majority of the proteins mutated in cancer are tumor suppressors which cannot 
be re-activated by small molecules. A possible solution is exploiting the fact that tumor 
suppressor gene inactivation results in activation of a downstream growth pathway. For 
example, PTEN mutations lead to increased activity of the downstream kinase AKT 8. In 
this study we sought to systematically identify tumor suppressor genes in melanoma and 
characterize the downstream pathways activated by their loss of function.
We compiled somatic mutation data from whole exome/genome sequence of 501 melanomas 
from various sources including The Cancer Genome Atlas (TCGA) 2,3. Data were analyzed 
as described previously 9 (Supplementary Table 1 and 2). Genes were ranked based on non-
synonymous mutation frequency, number of mutations per megabase and mutation burden 9. 
We then identified genes for which nonsense or frameshift mutations encompass at least 
20% of all its mutations, a suggested threshold for tumor suppressor genes 10. The highest 
ranking genes were TP53, NF1, ARID2, CDKN2A, and PTEN. After these, we found 
RASA2 was mutated in 5.4% of patients (Table 1) and 27% of those mutations were 
alterations leading to loss of function (LOF) (Table 1). The distribution of the 32 non-
synonymous mutations identified in RASA2 is shown in Fig. 1A. We profiled the copy 
number landscape of 22 samples using the CytoScan High Definition array (Affymetrix) and 
found 3 focal deletions (13.6%). Consistent with these data, examination of the melanoma 
TCGA copy number variation (CNV) data, showed deletions of the RASA2 locus in 11.7% 
of cases. Furthermore, RASA2 was found to be null in 1% of melanoma samples 
investigated, placing RASA2 in the top 10% of all homozygously deleted genes in the 
TCGA data (p<0.05). Thus, RASA2 is a potential tumor suppressor gene in melanoma 
(Table 1, Supplementary Table 2 and Supplementary Fig. 1).
RASA2 encodes a GTPase-activating protein (GAP), which stimulates the GTPase activity 
of wild-type (WT) RAS but not its mutated oncogenic form. Acting as a suppressor of RAS 
function, RASA2 enhances the weak intrinsic GTPase activity of RAS resulting in the 
inactive GDP-bound isoform 11. Importantly the role of RASA2 has never been investigated 
in melanoma. Recently, NF1, which encodes another RAS-specific GAP, has been found 
frequently mutated and to play a central role in melanoma 2,3. Mutations in RASA2 and 
NF1 co-occur strongly (p-value: 0.000011 [Fisher's Exact Test] (Fig. 1B; Supplementary 
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Table 3). Examination of publicly available databases revealed that RASA2 is mutated in 
several other tumor types (Supplementary Fig. 2).
To test whether RASA2 is a tumor suppressor in melanoma, we knocked down its 
expression in immortalized, non-tumorigenic NIH3T3 cells, using two short hairpin RNA 
(shRNA) constructs. RASA2 knockdown resulted in RAS activation (Supplementary Fig. 
3A), leading to increased cell growth on plastic and in soft agar (Supplementary Fig. 3B).
To characterize the tumorigenic effects of RASA2 in melanoma cells, we functionally 
characterized two recurrent RASA2 mutations: p.Arg310*, which causes RASA2 truncation, 
and p.Ser400Phe in the catalytic RAS-GAP domain. We established stable pooled clones 
expressing vector control, WT or mutant RASA2 in the melanoma cell lines A375 (BRAF 
V600E, NRAS WT, NF1 mutant), 501Mel (BRAF V600E, NRAS WT, NF1 WT), 108T 
(BRAF WT, NRAS WT, NF1 mutant) and 55T (BRAF WT, NRAS WT, NF1 mutant) which 
all express WT RASA2. We detected similar levels of overexpressed RASA2 protein in 
A375, 501Mel, 108T and 55T stable clone cell lines except for the p.Arg310* mutant in 
108T, which had increased protein expression (Supplementary Fig. 4). These clones were 
used for subsequent studies.
Since RASA2 encodes a RAS GAP, we hypothesized that RASA2 mutation or loss would 
alleviate RAS suppression. Indeed, modeling the RASA2 mutants on the structure of 
p120GAP 12 predicts that the RASA2 p.Arg310* mutant is unable to bind to Ras as it lacks 
the RAS-GAP, PH and BTK domains. Although the RASA2 p.Ser400Phe mutant is 
expected to bind Ras, the mutation is likely to affect the stabilization of its catalytic site, 
which may disturb structural changes necessary for GAP catalysis, leading to increased Ras 
activity (Supplementary Fig. 5). To test the effects of RASA2 on RAS, we conducted both 
gain and loss-of-function studies. Overexpression of WT RASA2 substantially suppressed 
RAS-GTP levels; in contrast, both RASA2 mutants failed to suppress RAS-GTP levels, 
demonstrating that these two mutations result in a clear loss of function (Fig. 1C and 
Supplementary Fig. 6A). The mutations were not found to have this effect in A375 cells due 
to their high BRAF activity. This is consistent with previous data indicating that above a 
certain threshold of active protein, RAS can lead to maximal pathway activation 13. The 
A375 clones were therefore not analyzed further in this study. Conversely, in melanoma cells 
that retained RASA2 expression, RNA interference (RNAi)-mediated suppression of 
RASA2 led to the activation of RAS in 501Mel and 108T (Fig. 1C middle, 1C right). 
Endogenous RASA2 in 55T was barely detectable by immunoblotting (Supplementary Fig. 
4B), for this reason, RASA2 knockdown in this cell line was not performed. Importantly, re-
introduction of WT RASA2 into melanoma cells that harbor RASA2 mutations (76T: 
p.Arg310* and C084: p.Ser400Phe) inhibited RAS activation (Supplementary Fig. 6B). 
These data confirm that RASA2 is a functional RAS GAP and that mutation or loss of 
RASA2 activates RAS in melanoma. The variation seen in the effects of RASA2 mutants on 
RAS-GTP levels are probably due to differences in the cells lines’ mutational background 
and variation in endogenous RASA2 protein abundance as these can modulate RAS-
complex formation and are important in context-dependent signaling, as shown by Kiel et al 
14. Furthermore, in some cases, the RASA2 mutants were found to enhance RAS-GTP 
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levels, suggesting that these variants may have dominant negative effects. This scenario has 
precedent and has been described for p53 and PTEN 15,16.
To examine the effects of RASA2 mutations on proliferation and colony forming ability, we 
investigated cell growth in vitro. In low serum-containing media, WT clones grew slower 
than mutant clones (Fig. 1D and Supplementary Fig. 7A). We also observed this difference 
in anchorage independent cell growth, where cells expressing mutant RASA2 formed a 
significantly higher number of colonies compared to WT RASA2 (Fig. 1E and 
Supplementary Fig. 7Ci; P < 0.005 t-test). In agreement with the tumor suppressor role of 
RASA2, overexpression of WT RASA2 in melanoma cells that harbor RASA2 mutations 
(C084 and 76T) led to reduced cell growth (Supplementary Fig. 7B) and diminished 
anchorage independent growth (Supplementary Fig. 7Cii).
As previous studies reported that activation of RAS increases cell migration 17, we 
examined whether mutated RASA2 had the same effect. After seeding 108T, 55T or 501Mel 
pooled clones in serum-free medium, WT RASA2 expression led to reduced cell migration, 
whereas mutant RASA2 expression failed to suppress migration (Supplementary Fig. 8; P < 
0.0001 t-test).
To validate the extent to which RASA2 protein expression is lost in human melanomas and 
to assess its prognostic potential, we performed RASA2 immunohistochemistry (IHC) on a 
set of AJCC stage III melanomas (Supplementary Fig. 9) 18 19 . We found that RASA2 
expression was negative in 33% (27 of 81) of cases and positive in 67% (54 of 81) of 
melanomas (Supplementary Fig. 9C). Kaplan-Meier plot and log-rank tests showed that loss 
of RASA2 expression (negative by IHC) was significantly associated with poorer survival, 
HR=0.42 (0.23-0.78), Log rank p=0.0043 (Fig. 1F). These results further emphasize the role 
of RASA2 loss in melanoma progression and indicate it has prognostic relevance.
The finding of common alterations in RASA2, together with functional data indicating its 
effect on cell growth and migration, suggest that RASA2 is an important tumor suppressor in 
human melanoma. Particularly important is the fact that RASA2 suppression provides an 
alternative mechanism of RAS activation. This study demonstrates that melanomas have 
somatic mutations in the RASA2 gene, which lead to impaired RASA2 activity and 
constitutive activation of RAS signaling.
Materials and Methods
Tumor tissues
All DNA samples used in this study were derived from metastases. Samples used for whole-
exome capture were extracted from cell lines established directly from patient tumors as 
described previously 20. DNA subjected to whole-genome sequencing was extracted from 
OCT embedded specimens as described previously 20. Tissue was further collected and cell 
lines established at QIMR Berghofer Medical Research Institute. All cell lines were 
established as described previously 21 with informed patient consent under a protocol 
approved by the QIMR Berghofer Medical Research Institute Human Research Ethics 
Committee.
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A subset of cell lines used in the study (108T, 55T and 76T) were derived from a panel of 
pathology-confirmed metastatic melanoma tumor resections collected from patients enrolled 
in IRB-approved clinical trials at the Surgery Branch of the National Cancer Institute. 
Pathology-confirmed melanoma cell lines were derived from mechanically or enzymatically 
dispersed tumor cells, which were then cultured in RPMI 1640 + 10% FBS at 37°C in 5% 
CO2 for 5-15 passages. The C084 cell line was established at QIMR Berghofer Medical 
Research Institute as described previously 21, with informed patient consent under a 
protocol approved by the QIMR Berghofer Medical Research Institute Human Research 
Ethics Committee. Cell lines genotypes are indicated in Supplementary Table 6. All cell 
lines have been tested negative for mycoplasma.
PCR, sequencing and mutational analysis
PCR and sequencing of RASA2 was done as previously described 22. Sequence traces were 
analyzed using the Mutation Surveyor software package (SoftGenetics). Primers used are 
listed in Supplementary Table 4. Data deposition: The sequence reported in this paper will 
be deposited in the dbSNP, ClinVar database.
Statistical analyses
To evaluate whether the frequency of somatic mutations is significantly higher than would 
be expected if the mutations were neutral, we performed the following statistical test. The 
null hypothesis was that the probability of a mutation at a specific base is the neutral rate of 
11.4 mutations/Mb (i.e. p=11.4e-6). We computed a one-sided p-value using the pbinom 
function in the R statistical software. To determine whether the ratio of nonsynonymous to 
synonymous mutations observed was statistically significant, the exact binomial test was 
used, with an expected ratio of 2.5:1 9. Sample size considered a binomial distribution based 
on the number of base pairs sequenced for the gene of interest, the number of mutations 
observed and the background rate of mutation. For the background rate, we used the 
observed rate in the exome screen: 11.2 mutations per Mb. With this study design, there is 
more than 99% probability of identifying a gene that is mutated at 1% or higher. All the 
statistical calculations were performed in the R statistical environment. Further statistical 
analyses were performed using Microsoft Excel to generate p-values to determine 
significance (two-tailed t-test). Red arrows in Figure 1 include frameshift, nonsense and 
deleterious mutations based on SIFT analysis.
CytoScan array processing and analysis
Samples were prepared according to Affymetrix protocols (Affymetrix, Inc). DNA quality 
and quantity was ensured using Bioanalyzer (Agilent, Inc) and NanoDrop (Thermo 
Scientific, Inc) respectively. Per DNA labeling, 200 nanograms of genomic DNA were used 
in conjunction with the Affymetrix recommended protocol for CytoScan HD array kit and 
reagents (catalog# 901835). The hybridization cocktail containing the fragmented and 
labeled DNAs was hybridized to The Affymetrix CytoScan HD GeneChip. The chips were 
washed and stained by the Affymetrix Fluidics Station using the standard format and 
protocols as described by Affymetrix. The probe arrays were stained with streptavidin 
phycoerythrin solution (Molecular Probes, Carlsbad, CA) and enhanced by using an 
antibody solution containing 0.5 mg/mL of biotinylated anti-streptavidin (Vector 
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Laboratories, Burlingame, CA). An Affymetrix Gene Chip Scanner 3000 was used to scan 
the probe arrays. The .Cel files were generated from the scanned images using Affymetrix 
AGCC software and the .cyhd.cychp files were generated by the Chromosome Analysis 
Suite (ChAS) Version 2.1 software.
All the analyses were done with ChAS default parameters for LOH and Copy Number State 
(CNS). A description of the samples used for this analysis is listed in Supplementary Table 
5.
Construction of wild-type and mutant RASA2 expression vectors
Human RASA2 cDNA (NM_006506) was cloned from HEK293T cDNA using PfuUltra II 
Hotstart PCR Master Mix (Agilent Technologies, Santa Clara, CA) according to 
manufacturers’ instructions and the forward and reverse primers in Supplementary Table 8. 
A FLAG tag was introduced onto the N-terminus of RASA2 during the cloning procedure. 
PCR products were cloned into the pCDF1-MCS2-EF1-Puro vector (Systems Biosciences, 
Inc., Mountain View, CA) via the XbaI and NotI restriction sites. The p.S400F mutation was 
introduced using fusion PCR site directed mutagenesis. The p.R310X mutation was created 
by using an alternative reverse primer to introduce the relevant nonsense mutation/stop 
codon.
Western blotting
501Mel, 108T and 55T cells stables with RASA2-FLAG (WT, mutant or empty vector) were 
gently washed 2X in PBS and then lysed using 1.0 ml 1% NP-40 lysis buffer (1% NP-40, 50 
mM Tris-HCl pH 7.5, 150 mM NaCl, Complete Protease Inhibitor tablet, EDTA-free 
(Roche, Indianapolis, IN), 1μM sodium orthovanadate, 1 mM sodium fluoride, and 0.1% β-
mercaptoethanol) per T-75 flask for 20 minutes on ice. Lysed cells were scraped and 
transferred into a 1.5 mL microcentrifuge tube. Extracts were centrifuged for 10 minutes at 
14,000 rpm at 4°C. Proteins (50 μg) were resolved on 10% SDS-polyacrylamide gels and 
transferred to nitrocellulose membranes (BioRad). Western blots were probed with the 
following antibodies anti-FLAG (M2) (Sigma-Aldrich) and GAPDH (Millipore). Ras-GTP 
levels were determined using a RAS activation Assay Kit (EMD Millipore). Every Ras-GTP 
assay was performed twice.
Pooled stable expression
To produce lentivirus, RASA2 constructs were co-transfected into HEK 293T cells seeded at 
2.5X106 per T75 flask with pVSV-G and pFIV-34N (kind gifts from Todd Waldman, 
Georgetown University) helper plasmids using Lipofectamine 2000 (Life Technologies) as 
described by the manufacturer. Virus-containing media was harvested 60 hr after 
transfection, filtered, aliquoted and stored at -80°C.
501Mel, 55T and 108T cells were grown in RPMI-1640 (Biological Industries) and 
supplemented with 10% fetal bovine serum (HyClone, Logan, UT). Lentivirus for RASA2 
(WT, p.Arg310* and S400F) and empty vector control were used to infect the cells as 
previously described 23. Stable expression of RASA2 proteins (WT and mutants) was 
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determined by SDS-PAGE analysis followed by immunoblotting with anti-FLAG and anti-
GAPDH to show equivalent expression among pools.
siRNA depletion of endogenous RASA2
Two human RASA2 specific siRNAs (ON-Targetplus) were designed using siRNA design 
program for human RASA2 and were purchased from Dharmacon (Thermo Fisher 
Scientific). The sequences of the two siRNAs used to transiently deplete RASA2 in 
malignant melanoma cells are found in Supplementary Table 7. Using DharmaFECT 
transfection reagent #1 (specific for siRNA), melanoma cells were transfected with 50 nM 
siRNA On target siRNA in the presence of OptiMEM-I medium (Life Technologies). Cells 
were incubated for 72 h post-transfection before checking RAS-GTP levels by the RAS 
Activation Assay Kit (Millipore).
Lentiviral shRNA
All shRNA expression constructs were obtained from Open Biosystems. Lentiviral stocks 
were prepared as previously described22. NIH 3T3 cells were infected with shRNA for each 
condition (vector control and two independent mouse RASA2-specific shRNAs) and 
selected as previously described 22. The shRNA constructs used in this study were: sh50 
(TRCN0000034350) and sh51 (TRCN0000034351).
3D Ras-RASA2 model prediction
The complex between human HRAS bound to guanosine triphosphatase (GTPase)-activating 
domain of the human GTPase-activating protein p120GAP (GAP-334), 1WQ1.pdb24, was 
used as a template to create both RASA2 (1WQ1 chain G, GAP-334) and Mg2+-NRAS-GTP 
(1WQ1 chain R, HRAS) models. GAP-334 sequence present in the PDB file is shorter than 
RASA2, but it covers the binding interface, is bound to RAS, and has high similarity with 
the query. Sequence alignment and homology modeling were performed with Prime (version 
4.0, Schrödinger, LLC, New York, NY, 2014). The initial X-ray structure 1WQ1 contains the 
substrate GDP-AlF3 bound to HRAS. AlF3 molecule, that is thought to mimic the γ-
phosphate moiety of GTP24, was manually replaced with the γ- phosphate group bound to 
GDP.
Hydrogen atoms and side chain orientations of the GTP-NRAS-RASA2 complex were 
optimized with the Protein Preparation Wizard tool from Schrödinger at physiological pH. 
Side chains were refined with the Predict Side Chains tool available in Prime.. Both 
complexes GTP-NRAS-(WT)RASA2 and GTP-NRAS-(S400F)RASA2 were then 
minimized to a derivative convergence of 0.05 kJ/mol-Å using the Polak-Ribiere Conjugate 
Gradient (PRCG) minimization algorithm, the OPLS2005 force field and the GB/SA water 
solvation model implemented in MacroModel (version 10.8, Schrödinger, LLC, New York, 
NY, 2014): the finger loop was set to be free to move, a shell 5 Å around the loop minimized 
applying a force constant of 200 kJ/molÅ2, and another shell of 5 Å with a constant force of 
300 kJ/molÅ2.
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Proliferation assays
To examine cell growth, melanoma cell lines (501Mel, 55T and 108T) stably infected with 
either vector, WT RASA2, p.Arg310* mutant or p.Ser400Phe mutant RASA2 were seeded 
in 6 replicates into 96 well plates at 200-2000 cells per well and incubated for 7-17 days. 
Samples were analyzed every 48 hrs by lysing cells in 50 μl 0.2% SDS/well and incubating 
for 2 hour at 37°C prior to addition of 150 μl/well of SYBR Green I solution (1:750 SYBR 
Green I (Invitrogen-Molecular Probes) diluted in dH20).
Soft agar assay
501Mel, 108T and 55T pooled RASA2 clones were plated in 4 replicates at 1000 cells/well 
in top plugs consisting of sterile 0.33% Bacto-Agar (BD, Sparks, MD) and 2.5% fetal bovine 
serum (HyClone, Logan, UT) in a 24-well plate. The lower plug contained sterile 0.5% 
Bacto-Agar and 2.5% fetal bovine serum. After one week, the colonies were counted.
Migration Assay
Blind well chemotaxis chambers with 13-mm diameter, 8mm pore size PVPF filters (Costar 
Scientific Co, Cambridge, MA) were used. Cells (2x105) suspended in serum free medium, 
were added to the upper chamber. 10% FBS full medium was placed in the lower chamber. 
Assays were carried out at 37 degrees in 5% CO2. After incubation (12-24h), the upper 
surface of the filter was freed of the cells by using a cotton swab. Cells that passed through 
the filter to the bottom side were fixed in methanol and then stained by Geimsa. Each 
triplicate assay was performed three times. Migrating cells were counted blindly in ten 
representative light-microscopy fields.
RASA2 immunohistochemistry
RASA2 immunohistochemistry (IHC) was performed on AJCC Stage III melanoma tumor 
microarrays (TMAs). It was performed using rabbit polyclonal anti-RASA2 antibody from 
Sigma-Aldrich (HPA035375) on a DAKO IHC autostainer using DAKO EnVison FLEX+ 
detection system (DAKO; K8002) with DAB as the chromogen (DAKO; K3467) as per the 
manufacturers’ instructions (high pH antigen retrieval, primary antibody dilution 1:100 for 
60 min). Resultant predominant IHC signal was cytoplasmic. Cases were scored as a percent 
of cytoplasmic positive tumor cells (0-100) and overall tumor staining intensity (0 - 4). 
Typically in positive samples, there was homogeneous staining across 100% of tumor cells. 
The intensity of staining varied between patients and ranged from negative (intensity = 0) to 
weakly positive (intensity 1 - 2) or strongly positive (intensity 3 - 4). Cases were scored as 
percent of cytoplasmic positive tumor cells (0-100) and overall tumor staining intensity (0 – 
4). The Kaplan Meier graph represents negative (intensity = 0) versus any positive (1-4).
TMA cohort description
Samples eligible for this TMA were obtained at the Melanoma Institute Australia 
Biospecimen Bank from AJCC stage-III (lymph node) metastatic melanoma specimens in 
which macroscopic tumor was observed, from patients believed to be without distant 
metastases at the time of tumor banking based on clinical examination and computerized 
axial tomographic scanning of the brain, chest, abdomen, and pelvis. Key covariates were 
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balanced in this cohort to permit survival analysis. These samples were used to derive Figure 
1F
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Figure 1. Effects of RASA2 mutations on RAS activity, growth and patient survival.
(A) Human RASA2 protein, conserved domains indicated as blocks: C2 domain first repeat 
(C2 1); C2 domain second repeat (C2 2); Ras-GTPase activating domain (RAS-GAP); 
Plekstrin homology domain (PH); Bruton’s tyrosine kinase Cys-rich motif (BTK). Somatic 
mutations indicated with arrows and amino-acid changes. Red triangles indicate deleterious 
mutations. Underlined mutations were functionally assessed. (B) Distribution of somatic 
mutations in BRAF, NRAS, NF1 and RASA2 in melanoma (n=501). (C) Immunoblot of 
RAS-GTP levels in 501Mel cells expressing the indicated constructs (left). 501Mel cells 
(middle) and 108T (right) cells depleted for RASA2 using human RASA2 siRNAs. RAS-
GTP levels were assessed by RAS pull-down assay and the RAS-GTP/RAS ratio of 2 
independent experiments were calculated and normalized to the vector control (lower panel). 
Error bars, standard deviation (S.D.) (D) 501Mel clones expressing the indicated constructs 
were seeded in 96-well plates in 2.5% FBS and average cell number was measured by 
assessing DNA content using SYBR Green I from two independent experiments with six 
repeats each. Error bars, standard deviation (S.D.).(E) Anchorage-independent proliferation 
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of 501Mel RASA2 clones expressing the indicated constructs was assessed by measuring 
colony formation in soft agar in 2.5% serum from two independent experiments four repeats 
each after 7 days. **P< 0.005 for WT vs. vector and ***P< 0.0001 for WT vs mutants 
(Students t-tests). (F) Kaplan-Meier curve showing overall survival of AJCC stage III 
melanoma patients with positive (n=54) or negative (n=27) RASA2 expression (log rank p = 
0.0043).
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Table 1
Melanoma driver genes that harbor at least 20% loss of function mutations
Gene name % of tumors with mutation % LOF of all coding mutations
TP53 17.1 33.3
NF1 14.4 42.0
ARID2 12.6 53.0
CDKN2A 12.4 57.6
PTEN 8.8 44.4
SETD2 5.4 32.4
RASA2 5.4 27.3
Genes were ranked based on the non-synonymous frequency, mutations per megabase, mutation rate (taking into account the base coverage) and 
presence of deleterious (nonsense or frameshift) mutations in at least 20% of the cases.
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